189 related articles for article (PubMed ID: 12390317)
1. Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection.
Burton CT; Hardy GA; Sullivan AK; Nelson MR; Gazzard B; Gotch FM; Imami N
Clin Exp Immunol; 2002 Nov; 130(2):286-92. PubMed ID: 12390317
[TBL] [Abstract][Full Text] [Related]
2. Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART.
Wasmuth JC; Nischalke HD; Jütte A; Fätkenheuer G; Salzberger B; Sauerbruch T; Spengler U; Rockstroh JK; Dumoulin FL
Antiviral Res; 2004 Mar; 61(3):207-12. PubMed ID: 15168802
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels and ex vivo production of beta-chemokines, interferon gamma, and interleukin 2 in advanced human immunodeficiency virus type 1 infection: the effect of protease inhibitor therapy.
De Luca A; Giancola ML; Cingolani A; Ammassari A; Murri R; Antinori A
AIDS Res Hum Retroviruses; 2000 Jun; 16(9):835-43. PubMed ID: 10875609
[TBL] [Abstract][Full Text] [Related]
4. Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
Carter LM; Peters BS; Ellis BA; Wolstencroft RA
J Infect; 2000 Nov; 41(3):252-5. PubMed ID: 11120614
[TBL] [Abstract][Full Text] [Related]
5. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
[TBL] [Abstract][Full Text] [Related]
6. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir.
Bisset LR; Rothen M; Joller-Jemelka HI; Dubs RW; Grob PJ; Opravil M
AIDS; 1997 Mar; 11(4):485-91. PubMed ID: 9084796
[TBL] [Abstract][Full Text] [Related]
7. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy.
Giovannetti A; Ensoli F; Mazzetta F; De Cristofaro M; Pierdominici M; Muratori DS; Fiorelli V; Aiuti F
Clin Exp Immunol; 1999 Oct; 118(1):87-94. PubMed ID: 10540164
[TBL] [Abstract][Full Text] [Related]
8. Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta.
Kumar D; Parato K; Kumar A; Sun E; Cameron DW; Angel JB
AIDS Res Hum Retroviruses; 1999 Aug; 15(12):1073-7. PubMed ID: 10461827
[TBL] [Abstract][Full Text] [Related]
9. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
[TBL] [Abstract][Full Text] [Related]
10. Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.
Sisay Z; Berhe N; Petros B; Tegbaru B; Messele T; Hailu A; Wolday D
Ethiop Med J; 2011 Jul; 49(3):179-86. PubMed ID: 21991751
[TBL] [Abstract][Full Text] [Related]
11. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy.
Blanco J; Cabrera C; Jou A; Ruiz L; Clotet B; Esté JA
AIDS; 1999 Apr; 13(5):547-55. PubMed ID: 10203379
[TBL] [Abstract][Full Text] [Related]
12. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy.
Pierdominici M; Giovannetti A; Ensoli F; Mazzetta F; Marziali M; De Cristofaro MR; Santini-Muratori D; Leti W; Aiuti F
J Acquir Immune Defic Syndr; 2002 Feb; 29(2):122-31. PubMed ID: 11832680
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
14. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases.
Ghani AC; Henley WE; Donnelly CA; Mayer S; Anderson RM
AIDS; 2001 Jun; 15(9):1133-42. PubMed ID: 11416715
[TBL] [Abstract][Full Text] [Related]
16. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
17. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.
Blanpain C; Migeotte I; Lee B; Vakili J; Doranz BJ; Govaerts C; Vassart G; Doms RW; Parmentier M
Blood; 1999 Sep; 94(6):1899-905. PubMed ID: 10477718
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kryst J; Kawalec P; Pilc A
PLoS One; 2015; 10(5):e0124279. PubMed ID: 25933004
[TBL] [Abstract][Full Text] [Related]
19. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
20. Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sullivan AK; Burton CT; Nelson MR; Moyle G; Mandalia S; Gotch FM; Gazzard BG; Imami N
Scand J Immunol; 2003 Jun; 57(6):600-7. PubMed ID: 12791099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
